Angiogenic factors in chronic lymphocytic leukaemia (CLL): Where do we stand?

Critical Reviews in Oncology/Hematology

Volumn 93, Issue 3, 2015, Pages 225-236

  Aguirre Palma, Luis Mario ^a   Gehrke, Iris ^b   Kreuzer, Karl Anton ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Angiogenesis; Angiogenic factors; Chronic lymphocytic leukaemia (CLL); Microenvironment; Pathological angiogenesis

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; ANGIOPOIETIN 1; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; ENDOTHELIAL LOCUS 1; FIBROBLAST GROWTH FACTOR 2; FLUDARABINE; FOLLISTATIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; LENALIDOMIDE; LEPTIN; MIDKINE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PLEIOTROPHIN; PROGRANULIN; PROLIFERIN; RITUXIMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CHRONIC LYMPHATIC LEUKEMIA; DRUG MECHANISM; DRUG TARGETING; HUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANGIOGENESIS INDUCING AGENTS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 84922451562     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.10.007     Document Type: Review

References (122)

1. Folkman J. Encyclopedia of genetics 2001, 66-73. Academic Press, New York, NY. S. Brenner, J.H. Miller (Eds.).
2. De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012, 44(1):1-9.
3. Albitar M. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol 2001, 106(4):170-176.
4. Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 2013, 88(9):803-816.
5. Kini A.R., Kay N.E., Peterson L.C. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000, 14(8):1414-1418.
6. Peterson L., Kini A.R., Kay N. Angiogenesis is increased in B-cell chronic lymphocytic leukemia. Blood 2001, 97(8):2529-2530.
7. Piechnik A., Dmoszynska A., Omiotek M., et al. The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int J Cancer 2013, 133(6):1489-1496.
8. Saharinen P., Eklund L., Pulkki K., Bono P., Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 2011, 17(7):347-362.
9. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008, 358(19):2039-2049.
10. Shibuya M., Claessonwelsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006, 312(5):549-560.
11. Ayad M.W., El Naggar A.A. Angiogenic factor VEGF and its relationship with biological prognostic markers in chronic lymphocytic leukemia. Egypt J Immunol Egypt Assoc Immunol 2010, 17(1):59-71.
12. Ferrara N., Hillan K.J., Gerber H-P., Novotny W. Case history: discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discovery 2004, 3(5):391-400.
13. Bogusz J., Majchrzak A., Medra A., Cebula-Obrzut B., Robak T., Smolewski P. Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells. Postȩpy Hig Med Dośw (Online) 2013, 67:107-118.
14. Bairey O., Boycov O., Kaganovsky E., Zimra Y., Shaklai M., Rabizadeh E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res 2004, 28(3):243-248.
15. Gehrke I., Gandhirajan R.K., Poll-Wolbeck S.J., Hallek M., Kreuzer K-A. Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells. Mol Med Camb Mass 2011, 17(7-8):619-627.
16. Lozano-Santos C., Martinez-Velasquez J., Fernandez-Cuevas B., et al. Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia. PLoS One 2014, 9(6).
17. Wróbel T., Mazur G., Dzietczenia J., Gebura K., Kuliczkowski K., Bogunia-Kubik K. VEGF and bFGF gene polymorphisms in Polish patients with B-CLL. Med Oncol Northwood Lond Engl 2013, 30(1):456.
18. Baban D., Murray J., Earl H., Kerr D., Seymour L. Quantitative analysis of vascular endothelial growth factor expression in chronic lymphocytic leukaemia. Int J Oncol 1996, 8(1):29-34.
19. Molica S., Vitelli G., Levato D., Gandolfo G.M., Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 1999, 107(3):605-610.
20. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23(5):1011-1027.
21. Itoh N., Ornitz D.M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem (Tokyo) 2011, 149(2):121-130.
22. Katoh M. Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells. Curr Pharm Biotechnol 2011, 12(2):160-170.
23. Aguayo A., Kantarjian H., Manshouri T., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96(6):2240-2245.
24. Smolej L., Andrýs C., Maisnar V., Pour L., Malý J. Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta Medica Hradec Král Univ Carol Fac Medica Hradec Král 2005, 48(1):57-58.
25. Menzel T., Rahman Z., Calleja E., et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996, 87(3):1056-1063.
26. König A., Menzel T., Lynen S., et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997, 11(2):258-265.
27. Smolej L., Andrýs C., Krejsek J., et al. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment. Vnitřní Lékařství 2007, 53(11):1171-1176.
28. Chanan-Khan A., Miller K.C., Musial L., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006, 24(34):5343-5349.
29. Maffei R., Fiorcari S., Bulgarelli J., et al. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Exp Hematol 2013, 42(2):126-136.
30. Li H., Fredriksson L., Li X., Eriksson U. PDGF-D is a potent transforming and angiogenic growth factor. Oncogene 2003, 22(10):1501-1510.
31. Antoniades H.N., Scher C.D., Stiles C.D. Purification of human platelet-derived growth factor. Proc Natl Acad Sci USA 1979, 76(4):1809-1813.
32. Zhang X., Nie D., Chakrabarty S. Growth factors in tumor microenvironment. Front Biosci J Virtual Libr 2010, 15:151-165.
33. Dong J., Grunstein J., Tejada M., et al. VEGF-null cells require PDGFR? signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004, 23(14):2800-2810.
34. Kwon H.J., Kim G-E., Lee Y.T., et al. Inhibition of platelet-derived growth factor receptor tyrosine kinase and downstream signaling pathways by Compound C. Cell Signal 2013, 25(4):883-897.
35. Ho C-L., Hsu L-F., Phyliky R.L., Li C-Y. Autocrine expression of platelet-derived growth factor B in B cell chronic lymphocytic leukemia. Acta Haematol 2005, 114(3):133-140.
36. Ding W., Knox T.R., Tschumper R.C., et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010, 116(16):2984-2993.
37. Gialeli C., Nikitovic D., Kletsas D., Theocharis A.D., Tzanakakis G.N., Karamanos N.K. PDGF/PDGFR signaling and targeting in cancer growth and progression: focus on tumor microenvironment and cancer-associated fibroblasts. Curr Pharm Des 2013, 20(17):2843-2848.
38. Malavaki C.J., Roussidis A.E., Gialeli C., et al. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells. FEBS J 2013, 280(10):2477-2489.
39. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372(6505):425-432.
40. Garofalo C., Surmacz E. Leptin and cancer. J Cell Physiol 2006, 207(1):12-22.
41. Lam Q.L.K., Wang S., Ko O.K.H., Kincade P.W., Lu L. Leptin signaling maintains B-cell homeostasis via induction of Bcl-2 and Cyclin D1. Proc Natl Acad Sci USA 2010, 107(31):13812-13817.
42. Sierra-Honigmann M.R., Nath A.K., Murakami C., et al. Biological action of leptin as an angiogenic factor. Science 1998, 281(5383):1683-1686.
43. Bennett B.D., Solar G.P., Yuan J.Q., Mathias J., Thomas G.R., Matthews W. A role for leptin and its cognate receptor in hematopoiesis. Curr Biol (CB) 1996, 6(9):1170-1180.
44. Pamuk G.E., Demir M., Harmandar F., Yesil Y., Turgut B., Vural O. Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 2006, 28(3):241-244.
45. Dalamaga M., Crotty B.H., Fargnoli J., et al. B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin levels: a case-control study in Greece. Cancer Causes Control (CCC) 2010, 21(9):1451-1459.
46. Avalos B.R. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 1996, 88(3):761-777.
47. Demetri G.D., Griffin J.D. Granulocyte colony-stimulating factor and its receptor. Blood 1991, 78(11):2791-2808.
48. Bennett C.L., Djulbegovic B., Norris L.B., Armitage J.O. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 2013, 368(12):1131-1139.
49. Martino M., Fedele R., Massara E., Recchia A.G., Irrera G., Morabito F. Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?. Expert Opin Biol Ther 2012, 12(5):609-621.
50. Calandra G., Bridger G., Fricker S. CXCR4 in clinical hematology. The chemokine system in experimental and clinical hematology. Current topics in microbiology and immunology 2010, 173-191. Springer, Berlin Heidelberg. O. Bruserud (Ed.).
51. Gruber M., Fleiss K., Porpaczy E., et al. Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab. Ann Hematol 2011, 90(10):1131-1136.
52. Bartholin L., Guindon S., Martel S., Corbo L., Rimokh R. Identification of NF-kappaB responsive elements in follistatin related gene (FLRG) promoter. Gene 2007, 393(1-2):153-162.
53. Maguer-Satta V., Bartholin L., Jeanpierre S., et al. During hematopoiesis, expression of FLRG, a novel activin A ligand, is regulated by TGF-β. Exp Hematol 2001, 29(3):301-308.
54. De Kretser D.M., O'Hehir R.E., Hardy C.L., Hedger M.P. The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol Cell Endocrinol 2012, 359(1-2):101-106.
55. Phillips D.J. Regulation of activin's access to the cell: why is Mother Nature such a control freak?. BioEssays 2000, 22(8):689-696.
56. Bartholin L., Maguer-Satta V., Hayette S., et al. Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function. Oncogene 2002, 21(14):2227-2235.
57. Hayette S., Gadoux M., Martel S., et al. FLRG (follistatin-related gene), a new target of chromosomal rearrangement in malignant blood disorders. Oncogene 1998, 16(22):2949-2954.
58. Zipori D., Barda-Saad M. Role of activin A in negative regulation of normal and tumor B lymphocytes. J Leukoc Biol 2001, 69(6):867-873.
59. Maguer-Satta V., Rimokh R. FLRG, member of the follistatin family, a new player in hematopoiesis. Mol Cell Endocrinol 2004, 225(1-2):109-118.
60. Kawaguchi M., Sugaya M., Suga H., et al. Serum levels of angiopoietin-2, but not angiopoietin-1, are elevated in patients with erythrodermic cutaneous T-cell lymphoma. Acta Derm Venereol 2013.
61. Yu X., Seegar T.C.M., Dalton A.C., et al. Structural basis for angiopoietin-1-mediated signaling initiation. Proc Natl Acad Sci USA 2013, 110(18):7205-7210.
62. Moss A. The angiopoietin:Tie 2 interaction: a potential target for future therapies in human vascular disease. Cytokine Growth Factor Rev 2013, 24(6):579-592.
63. Seegar T.C.M., Eller B., Tzvetkova-Robev D., et al. Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell 2010, 37(5):643-655.
64. Martinelli S., Kanduri M., Maffei R., et al. ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. Epigenetics 2013, 8(7).
65. Maffei R., Martinelli S., Castelli I., et al. Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk Res 2010, 34(3):312-321.
66. Maffei R., Martinelli S., Santachiara R., et al. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood 2010, 116(4):584-592.
67. Kay N.E., Bone N.D., Tschumper R.C., et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002, 16(5):911-919.
68. Musolino C., Alonci A., Bellomo G., et al. Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur J Haematol 2004, 72(6):416-419.
69. Thiyagarajan N., Acharya K.R. Crystal structure of human angiogenin with an engineered loop exhibits conformational flexibility at the functional regions of the molecule. FEBS Open Biol 2012, 3:65-70.
70. Gao X., Xu Z. Mechanisms of action of angiogenin. Acta Biochim Biophys Sin 2008, 40(7):619-624.
71. Molica S., Vitelli G., Levato D., et al. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression. Eur J Haematol 2004, 73(1):36-42.
72. Pavlov N., Badet J. L'angiogénine: implication dans l'angiogenèse et le développement tumoral. Bull Cancer (Paris) 2001, 88(8):725-732.
73. Gao X., Hu H., Zhu J., Xu Z. Identification and characterization of follistatin as a novel angiogenin-binding protein. FEBS Lett 2007, 581(28):5505-5510.
74. Cohen S., Shoshana O., Zelman-Toister E., et al. The cytokine midkine and its receptor RPTP? Regulate B cell survival in a pathway induced by CD74. J Immunol (Baltimore, MD: 1950) 2012, 188(1):259-269.
75. Kadomatsu K., Hagihara M., Akhter S., Fan Q.W., Muramatsu H., Muramatsu T. Midkine induces the transformation of NIH3T3 cells. Br J Cancer 1997, 75(3):354-359.
76. Shachar I., Cohen S., Marom A., Becker-Herman S. Regulation of CLL survival by hypoxia-inducible factor and its target genes. FEBS Lett 2012, 586(18):2906-2910.
77. Hidaka H., Yagasaki H., Takahashi Y., et al. Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia. Leuk Res 2007, 31(8):1045-1051.
78. Ohuchida T., Okamoto K., Akahane K., et al. Midkine protects hepatocellular carcinoma cells against TRAIL-mediated apoptosis through down-regulation of caspase-3 activity. Cancer 2004, 100(11):2430-2436.
79. Besse S., Comte R., Fréchault S., Courty J., Joël de L., Delbé J. Pleiotrophin promotes capillary-like sprouting from senescent aortic rings. Cytokine 2013, 62(1):44-47.
80. Mikelis C., Sfaelou E., Koutsioumpa M., Kieffer N., Papadimitriou E. Integrin ανβ3 is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase β/ζ. FASEB J 2009, 23(5):1459-1469.
81. Kong Y., Bai P., Nan K., Sun H., Chen N., Qi X. Pleiotrophin is a potential colorectal cancer prognostic factor that promotes VEGF expression and induces angiogenesis in colorectal cancer. Int J Colorectal Dis 2012, 27(3):287-298.
82. Du C., Wang L., Li Y., et al. Elevated expression of pleiotrophin in lymphocytic leukemia CD19+ B cells. APMIS 2014, 122(10):905-913.
83. Lu Y., Zheng L., Zhang W., et al. Growth factor progranulin contributes to cervical cancer cell proliferation and transformation in vivo and in vitro. Gynecol Oncol 2014, 134(2):364-371.
84. DeMorrow S. Progranulin: a novel regulator of gastrointestinal cancer progression. Transl Gastrointest Cancer 2013, 2(3):145-151.
85. Tang W., Lu Y., Tian Q.-Y., et al. The growth factor progranulin binds to tnf receptors and is therapeutic against inflammatory arthritis in mice. Science 2011, 332(6028):478-484.
86. Maas C., Tromp J.M., van Laar J., et al. CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex. Cell Death Dis 2013, 4(8):e782.
87. Göbel M., Eisele L., Möllmann M., et al. Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia. PLoS One 2013, 8(8):e72107.
88. Toft D.J., Rosenberg S.B., Bergers G., Volpert O., Linzer D.I.H. Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression. Proc Natl Acad Sci USA 2001, 98(23):13055-13059.
89. El-Shewy H.M., Luttrell L.M. Insulin-like growth factor-2/mannose-6 phosphate receptors. Insulin and IGFs 2009, vol. 80:667-697. Academic Press, Oxford, UK, (Chapter 24). L. Gerald (Ed.).
90. Vignon F., Rochefort H. Interactions of pro-cathepsin D and IGF-II on the mannose-6-phosphate/IGF-II receptor. Breast Cancer Res Treat 1992, 22(1):47-57.
91. Yang X., Qiao D., Meyer K., Pier T., Keles S., Friedl A. Angiogenesis induced by signal transducer and activator of transcription 5A (STAT5A) is dependent on autocrine activity of proliferin. J Biol Chem 2012, 287(9):6490-6502.
92. Hanayama R., Tanaka M., Miwa K., Nagata S. Expression of developmental endothelial locus-1 in a subset of macrophages for engulfment of apoptotic cells. J Immunol 2004, 172(6):3876-3882.
93. Kim K-J., Cho C-S., Kim W-U. Role of placenta growth factor in cancer and inflammation. Exp Mol Med 2012, 44(1):10-19.
94. Reinart N., Nguyen P-H., Boucas J., et al. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. Blood 2013, 121(5):812-821.
95. Maffei R., Bulgarelli J., Fiorcari S., et al. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica 2013, 98(7):1115-1123.
96. Nielsen D.L., Sengeløv L. Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy. Exp Opin Biol Ther 2012, 12(6):795-804.
97. Zins K., Thomas A., Lucas T., Sioud M., Aharinejad S., Abraham D. Inhibition of stromal PLGF suppresses the growth of prostate cancer xenografts. Int J Mol Sci 2013, 14(9):17958-17971.
98. Munnink T.H.O., Tamas K.R., Hooge M.N.L., et al. Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441. J Nucl Med 2013, 54(6):929-935.
99. Ho H-K.V., Jang J.J., Kaji S., et al. Developmental endothelial locus-1 (Del-1), a novel angiogenic protein its role in ischemia. Circulation 2004, 109(10):1314-1319.
100. Aoka Y., Johnson F.L., Penta K., et al. The embryonic angiogenic factor Del1 accelerates tumor growth by enhancing vascular formation. Microvasc Res 2002, 64(1):148-161.
101. Ciucurel E.C., Sefton M.V. Del-1 overexpression in endothelial cells increases vascular density in tissue-engineered implants containing endothelial cells and adipose-derived mesenchymal stromal cells. Tissue Eng, A 2013, 20(7-8):1235-1252.
102. Kay N.E., Shanafelt T.D., Strege A.K., Lee Y.K., Bone N.D., Raza A. Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an angiogenic switch. Leuk Res 2007, 31(7):899-906.
103. Cinamon G., Shinder V., Alon R. Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat Immunol 2001, 2(6):515-522.
104. Eikesdal H.P., Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol 2009, 19(5):310-317.
105. Haugsten E.M., Wiedlocha A., Olsnes S., Wesche J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 2010, 8(11):1439-1452.
106. Bouloumié A., Drexler H.C.A., Lafontan M., Busse R. Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 1998, 83(10):1059-1066.
107. Malli F., Papaioannou A.I., Gourgoulianis K.I., Daniil Z. The role of leptin in the respiratory system: an overview. Respir Res 2010, 11(1):152.
108. Krneta J., Kroll J., Alves F., et al. Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors. Cancer Res 2006, 66(11):5686-5695.
109. Davis S., Aldrich T.H., Jones P.F., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87(7):1161-1169.
110. Dumont D.J., Gradwohl G., Fong G.H., et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994, 8(16):1897-1909.
111. Jones N., Chen S.H., Sturk C., et al. A unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function. Mol Cell Biol 2003, 23(8):2658-2668.
112. Tadros A., Hughes D.P., Dunmore B.J., Brindle N.P.J. ABIN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-1. Blood 2003, 102(13):4407-4409.
113. Dai L-C. Midkine translocated to nucleoli and involved in carcinogenesis. World J Gastroenterol (WJG) 2009, 15(4):412-416.
114. You Z., Dong Y., Kong X., Beckett L.A., Gandour-Edwards R., Melamed J. Midkine is a NF-?B-inducible gene that supports prostate cancer cell survival. BMC Med Genomics 2008, 1:6.
115. Koutsioumpa M., Drosou G., Mikelis C., et al. Pleiotrophin expression and role in physiological angiogenesis in vivo: potential involvement of nucleolin. Vasc Cell 2012, 4:4.
116. Polykratis A., Katsoris P., Courty J., Papadimitriou E. Characterization of heparin affin regulatory peptide signaling in human endothelial cells. J Biol Chem 2005, 280(23):22454-22461.
117. He Z., Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med 2003, 81(10):600-612.
118. Serrero G. Autocrine growth factor revisited: PC-cell-derived growth factor (progranulin), a critical player in breast cancer tumorigenesis. Biochem Biophys Res Commun 2003, 308(3):409-413.
119. Brockman J.L., Schroeder M.D., Schuler L.A. PRL activates the cyclin D1 promoter via the Jak2/stat pathway. Mol Endocrinol 2002, 16(4):774-784.
120. Yang X., Zhang Y., Yang Y., et al. Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc Natl Acad Sci USA 2013, 110(34):13932-13937.
121. Fischer C., Jonckx B., Mazzone M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131(3):463-475.
122. Penta K., Varner J.A., Liaw L., Hidai C., Schatzman R., Quertermous T. Del1 induces integrin signaling and angiogenesis by ligation of αVβ3. J Biol Chem 1999, 274(16):11101-11109.